Keeping the Workforce: the Drug Industry's Cognitive Dissonance Problem
Amidst the mounting attacks on the drug industry by respected mass market publications and broadcast news, it is growing increasingly difficult for those in the industry to maintain the personal mission of "doing good" that--at least partly--attracted them to the pharmaceutical business. In the past, attractive option packages might have helped executives deal with uneasiness about some of the strategies being pursued by companies under the gun of blockbuster economics. But with stock prices low, that source of comfort has been removed--raising doubts about the industry's ability to retain its best and brightest.
You may also be interested in...
At Windhover's annual Marketing Pharmaceutical Innovation (MPI) conference in November, industry executives wrestled with an emerging dilemma -- how to win managed care's support for drugs that exhibit only minor improvements to existing products, while new over-the-counter (OTC) options surface.
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.